Investor Presentation First Nine Months of 2022
12
Investor presentation First nine months of 2022
Novo NordiskⓇ
ONWARDS 5 met its primary endpoint and demonstrated
superior HbA1c reduction vs once-daily basal insulin analogues
Change from baseline (%)
Superior reduction in HbA1c from baseline over time 52 weeks
Time since randomisation (weeks)
0
13
0.0
-0.4
-0.8
-1.2
-1.6
26
39
HH HH
52
52*
HHHH
-1.31%
■-1.68%
-2.0
Once-weekly insulin icodec
Once-daily basal insulin
Note: Overall baseline HbA1c of 8.9%
Highlights from the trial (includes real-world elements)
Inclusion criteria (1,085 participants):
Insulin-naïve people with type 2 diabetes
No limitations on use of oral antidiabetic treatments
Age ≥ 18 years, HbA1c > 7.0%
Endpoints:
Once-weekly insulin icodec achieved a superior reduction in
estimated HbA1c of -1.68%-points compared with -1.31%-points
for the once-daily basal insulins (ETD: -0.38%-points)
Icodec achieved a superior improvement in health-related quality
of life (DTSQ score) and compliance (TRIM-D score) questionnaires
Safety:
No statistically significant difference in estimated rates of severe
or clinically significant hypoglycaemia events
In the trial, once-weekly insulin icodec appeared to have a safe
and well-tolerated profile
*Lines are based on observed data where the value denoted after 52 weeks is estimated mean value derived based on multiple imputation
ETD: Estimate treatment difference; DTSQ: Diabetes Treatment Satisfaction Questionnaire; TRIM-D: Treatment Related Impact Measures in Diabetes (measuring an overall treatment compliance score)
Note: The trial investigated once-weekly insulin icodec in combination with a dosing guide app versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300) in a clinical practice settingView entire presentation